摘要
目的探讨米氮平联合帕罗西汀治疗抑郁症患者伴睡眠障碍的临床效果。方法选取2019年1月至2020年1月营口市第四人民医院收治的96例抑郁症伴睡眠障碍患者作为研究对象,采用随机数字表法将其分为观察组(48例)和对照组(48例)。对照组患者采用帕罗西汀方法治疗,观察组患者采用帕罗西汀联合米氮平方法治疗。比较两组患者治疗后的临床疗效,比较两组患者治疗前后的抑郁自评量表(SDS)、汉密尔顿抑郁量表(HAMD)和匹兹堡睡眠质量指数量表(PSQI)评分。结果观察组患者的临床治疗总有效率(91.7%)高于对照组(79.2%),差异有统计学意义(P<0.05)。治疗后,观察组患者的SDS评分低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗4、8周的HAMD评分和PSQI评分低于对照组,差异有统计学意义(P<0.05)。结论米氮平联合帕罗西汀治疗抑郁症伴随睡眠障碍患者,可有效减轻患者的抑郁症状,改善抑郁情绪和睡眠质量,临床疗效显著,值得临床推广。
Objective To investigate the clinical effect of Mirtazapine combined with Paroxetine in the treatment of depressive patients with sleep disorder.Methods A total of 96 patients with depression with sleep disorder treated in Yingkou Fourth People's Hospital from January 2019 to January 2020 were selected as the research objects.They were divided into observation group(48 cases)and control group(48 cases)by random number table method.The control group was treated with Paroxetine,and the observation group was treated with Paroxetine combined with Mirtazapine.The clinical efficacy was compared between the two groups after treatment,and the scores of self-rating depression scale(SDS),Hamilton depression scale(HAMD)and Pittsburgh sleep quality index(PSQI)were compared between the two groups before and after treatment.Results The total effective rate of observation group(91.7%)was higher than that of control group(79.2%),and the difference was statistically significant(P<0.05).After treatment,SDS score of observation group was lower than that in the control group,the difference was statistically significant(P<0.05).HAMD score and PSQI score in the observation group were lower than those in the control group at 4 and 8 weeks after treatment,the differences were statistically significant(P<0.05).Conclusion Mirtazapine combined with Paroxetine in the treatment of depressive patients with sleep disorder can effectively reduce depressive symptoms,improve depression mood and sleep quality,with significant clinical efficacy,worthy of clinical promotion.
作者
栾磊
王艳茹
LUAN Lei;WANG Yanru(Department of Psychology,the Fourth People′s Hospital of Yingkou City,Liaoning Province,Yingkou115000,China;Department of Medical Oncology,Anshan Tumor Hospital,Liaoning Province,Anshan114000,China)
出处
《中国当代医药》
CAS
2022年第10期71-74,共4页
China Modern Medicine
基金
国家创新药重点监测专项科研基金项目(E-2018-32-180020)。
关键词
米氮平
帕罗西汀
抑郁症
睡眠障碍
随机对照研究
Mirtazapine
Paroxetine
Depression
Sleep disorders
Randomized controlled study
作者简介
通讯作者:王艳茹。
